Clinical Trial Update: A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating TCD601 (Siplizumab) in new-onset Type 1 diabetes patients has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• TCD601 (Siplizumab) (Siplizumab)

Snippet

Sponsor: ITB-Med LLC | Conditions: Diabetes Mellitus, Type 1 | Phase 2 | Status: TERMINATED